3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
PRX-PLUS has a unique product feature with its deep-impacting formula
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
Revolutionary technology will further boost OneSource’s scientific services offerings
The pooled prevalence of GERD in the Indian population is 15.6 %
Subscribe To Our Newsletter & Stay Updated
